Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end
Posted In: PALI